Quan Anh Vu bought $105k of MNPR
Chief Financial Officer at Monopar Therapeutics. 1,500 shares at an average of $69.95, traded Dec 26, 2025, filed Dec 29, 2025.
Score components
- +22RoleCFO
- +10Trade size$105k at market
- +8Relative to holdingsFirst purchase: no shares before this trade
- +8Price context33% below the 52-week high
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +2.8%, 3m -18.7%, 6m +44.2%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001437749-25-038804, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 26, 2025 | POpen-market purchase Common Stock | +1,500 | $69.95 | $105k | 1,500 | Dec 29, 2025 |
Related signals
Other insiders at Monopar Therapeutics and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 28Weak | Monopar Therapeutics | Christopher M Starr director | $659k 8,400 shares | -62% | |
| 28Weak | Monopar Therapeutics | Chandler Robinson Chief Executive Officer | $2.6M 29,056 shares | -23% | |
| 20Weak | Monopar Therapeutics | Raymond Anderson director | $352k 3,142 shares | -37% | |
| 32Weak | Monopar Therapeutics | Kim R Tsuchimoto director | $456k 4,090 shares | -100% | |
| 30Weak | Monopar Therapeutics | Raymond Anderson director | $351k 3,142 shares | -12% | |
| 37Weak | Monopar Therapeutics | Kim R Tsuchimoto director | $456k 4,090 shares | -36% | |
| 0Weak | Monopar Therapeutics | Patrice Rioux other | $111 1 shares | -0% | |
| 40Moderate | MNPRsell Monopar Therapeutics | Arthur J Klausner director | $344k 5,121 shares | -37% | |
| 70Notable | MNPRsell Monopar Therapeutics | Chandler Robinson Chief Executive Officer | $35M 550,229 shares | -67% | |
| 65Notable | Monopar Therapeutics | Chandler Robinson Chief Executive Officer | $672k 16,800 shares | -19% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.